| Date |
Title |
| 5 Sep 2023 |
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer |
| 28 Aug 2023 |
Illumina To Webcast Upcoming Investor Conference |
| 17 Aug 2023 |
Illumina expands genomics capabilities in India with opening of Solutions Center |
| 11 Aug 2023 |
Illumina To Webcast Upcoming Investor Conference |
| 9 Aug 2023 |
Dr. Steven Barnard Appointed Chief Technology Officer |
| 9 Aug 2023 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023 |
| 25 Jul 2023 |
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options |
| 18 Jul 2023 |
Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 |
| 18 Jul 2023 |
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck |
| 11 Jul 2023 |
Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery |
| 11 Jun 2023 |
Illumina announces CEO transition plan |
| 5 Jun 2023 |
Illumina releases 2022 Corporate Social Responsibility Report |
| 2 Jun 2023 |
Illumina's Board of Directors elects two experienced Independent Directors to Board |
| 1 Jun 2023 |
Illumina unveils AI software to predict disease-causing genetic mutations in patients |
| 31 May 2023 |
Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023 |
| 30 May 2023 |
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing |
| 25 May 2023 |
Illumina announces preliminary results of annual meeting |
| 18 May 2023 |
Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees |
| 16 May 2023 |
Illumina's genomic technologies enable better pathogen preparedness and response |
| 15 May 2023 |
Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience |
| 12 May 2023 |
Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees |
| 8 May 2023 |
Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan" |
| 2 May 2023 |
Illumina increases equitable access to STEM education, reaching over 1 million learners |
| 1 May 2023 |
Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card |
| 25 Apr 2023 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth |
| 20 Apr 2023 |
Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees |
| 12 Apr 2023 |
Illumina's cloud-based informatics programs recognized for robust, international data privacy protections |
| 11 Apr 2023 |
Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients |
| 5 Apr 2023 |
Illumina celebrates 25 years of innovation |
| 4 Apr 2023 |
Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023 |
| 4 Apr 2023 |
Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023 |
| 3 Apr 2023 |
Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024 |
| 30 Mar 2023 |
Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee |
| 27 Mar 2023 |
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease |
| 24 Mar 2023 |
Illumina Issues Statement in Response to Carl Icahn's Letter |
| 20 Mar 2023 |
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements |
| 14 Mar 2023 |
Illumina launches its first product enabling long- and short-read sequencing on one instrument |
| 13 Mar 2023 |
Illumina Responds to Icahn Partners' Nomination of Directors |
| 2 Mar 2023 |
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States |
| 27 Feb 2023 |
Illumina To Webcast Upcoming Investor Conference |
| 8 Feb 2023 |
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute |
| 7 Feb 2023 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022 |
| 1 Feb 2023 |
Illumina Appoints Joydeep Goswami Chief Financial Officer |
| 10 Jan 2023 |
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 |
| 9 Jan 2023 |
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen |